Skip to main content
. Author manuscript; available in PMC: 2017 Jun 19.
Published in final edited form as: Oncogene. 2016 Dec 19;36(23):3263–3273. doi: 10.1038/onc.2016.471

Figure 8. Inhibition of RALB activity with dinaciclib potently suppresses leukemic colony formation in vitro and prevents NRI AML relapse in vivo.

Figure 8

(a) Leukemia-colony forming cell (L-CFC) frequencies for splenocytes harvested from leukemic mice treated for 16 hours with dinaciclib, ABT-737, or ABT-199 relative to DMSO vehicle controls (n = 3 independent experiments, error bars = 1 standard deviation, * P < 0.05) (c) White blood cell counts (WBC) of leukemic NRG mice transplanted with a 1:1 mix of NRD and NRI1 AML cells treated with control vehicle, continuous doxycycline (Dox) to suppress NRAS(V12) expression, or 5 days per week of 15 mg/kg/day dinaciclib (each symbol represents an individual mouse, bars = mean +/− 1 standard deviation, * P < 0.05 between Dox and dinaciclib treated mice).